Tyra Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tyra Biosciences, Inc. on April 2, 2026, covering events occurring on April 1, 2026. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol TYRA. It is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
On April 1, 2026, the Board of Directors designated Julia Rueb as the Company's principal accounting officer, succeeding Alan Fuhrman in that specific role. Mr. Fuhrman continues to serve as the Company's principal financial officer and Chief Financial Officer.
Management Commentary and Risks
The filing details the professional background of Ms. Rueb, who has served as Vice President, Finance since January 2024. Her prior experience includes roles at SOAProjects, Inc., van den Boom & Associates LLC, and Ernst & Young LLP. She holds a Master's degree in Accounting and is a Certified Public Accountant. The filing states she has no family relationships with the Company's directors or executive officers. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of Julia Rueb's appointment as principal accounting officer (April 1, 2026).
- Verify that Alan Fuhrman retains his title as Chief Financial Officer and principal financial officer.
- Review Ms. Rueb's prior experience in the life sciences industry and her CPA certification.
- Check for any subsequent filings regarding the transition of accounting responsibilities.